LEARN MORE ABOUT CURRENT ANALYTICAL METHODS FOR AAV CHARACTERIZATION AND HOW TO ENSURE COMPARABILITY, PERFORM PROPER SAFETY AND EFFICACY EVALUATIONS FOR YOUR GENE THERAPY PRODUCTS WITH EXPERTS FROM PROGEN.
Are you struggling with the selection of the right analytical methods for your gene therapy projects? Would you like to learn more about advantages of the in process controls and standards to ensure comparability of your data for safety and efficacy evaluation?
AAV gene therapy represents one of the most promising tools for gene delivery in modern medicine to date. However, the great influx of new technologies and the steady adjustments of guidelines concerning safety and efficacy of AAV gene therapies can be challenging.
Within the multitude of possibilities, there are common benchmarks to be considered that can support you to meet the criteria of regulatory authorities.
Join us as a panel of experts in AAV analytics discuss the advantages of using the right in-process controls and standards for your project. The panel of industry leaders will also share insights into analytical AAV tools and how they can support meeting the requirements which need to be met to allow the development of safe and efficient AAV gene therapies.
WHAT TO EXPECT
Part 1: The panel gives an overview of current analytical methods for AAV characterization and discuss the relevance of in-process controls and proper standards, including:
AAV analytical methods – advantages and disadvantages and the importance of using orthogonal methods
In-process control: how the use of proper in-process control can help you save time and precious sample volume.
AAV ELISA: why ELISAs are still the most commonly used choice for AAV capsid titer determination?
Internal AAV gold standard material: how PROGEN characterizes internal gold standards and continuously validates the data using orthogonal methods.
AAV standards: importance of standards for data comparability and how PROGEN ensures reliability
AAV antibodies: establishment of human chimeric AAV antibodies for use in serological assays
Part 2: The speakers answer audience questions with an interactive Q&A
MEET THE PANEL
Head of Product Management
Junior Product Manager
CEO & Founder
This webinar is brought to you in partnership with PROGEN.
Xavier De Mollerat Du Jeu, Senior Director R&D at Thermo Fisher Scientific is accompanied by Gianluca Pettiti, Executive Vice President and President, Life Sciences Group at Thermo Fisher Scientific and Fred Parietti, Co-Founder and CEO at Multiply Labs for this Workshop at Advanced Therapies Week 2024.
Manufacturing capacity, complexity and cost are core constraints that limit commercialization of cell and gene therapies, and ultimately patient access. In this Fireside Chat series, join Georgi Makin, VP of Digital & Editorial at Phacilitate and the Germfree team as we discuss the challenges and opportunities associated with delivering cell therapies in a decentralized manufacturing model.